创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

吴瑞红, 张磊, 丁艳华, 牛俊奇. 非酒精性脂肪性肝病无创诊断研究进展[J]. 药学进展, 2020, 44(3): 164-178.
引用本文: 吴瑞红, 张磊, 丁艳华, 牛俊奇. 非酒精性脂肪性肝病无创诊断研究进展[J]. 药学进展, 2020, 44(3): 164-178.
WU Ruihong, ZHANG Lei, DING Yanhua, NIU Junqi. Research Progress in Non-invasive Diagnosis of Non-alcoholic Fatty Liver Disease[J]. Progress in Pharmaceutical Sciences, 2020, 44(3): 164-178.
Citation: WU Ruihong, ZHANG Lei, DING Yanhua, NIU Junqi. Research Progress in Non-invasive Diagnosis of Non-alcoholic Fatty Liver Disease[J]. Progress in Pharmaceutical Sciences, 2020, 44(3): 164-178.

非酒精性脂肪性肝病无创诊断研究进展

Research Progress in Non-invasive Diagnosis of Non-alcoholic Fatty Liver Disease

  • 摘要: 非酒精性脂肪性肝病是全球最常见的慢性肝病。据估计,全球约25%的成年人患有非酒精性脂肪性肝病,且患病率逐年增加。非酒精性脂肪性肝病的疾病谱涵盖非酒精性脂肪肝、非酒精性脂肪性肝炎、非酒精性脂肪性肝炎相关纤维化、肝硬化和肝细胞癌。肝活检作为非酒精性脂肪性肝病诊断和分期的“金标准”,因有创性、取样变异和评价不一致等局限性限制了其广泛应用。随着进展为非酒精性脂肪性肝炎的患者数量增加,特别是疾病严重程度较重的病人增多,临床上迫切需要有效治疗药物,也迫切需要开发无创标志物来筛查、诊断、监测患者和判断疗效。对非酒精性脂肪性肝病的无创诊断研究进展进行综述,包括对脂肪变的评估、非酒精性脂肪性肝炎的诊断和纤维化的评估。

     

    Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide with an increasing rate of morbidity year by year, affecting 25% of the global adult population. Its disease spectrum covers non-alcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), NASH-related fibrosis, cirrhosis and hepatocellular carcinoma. Liver biopsy, as the "gold standard" for the diagnosis and staging of NAFLD, could not be widely used because of its limitations such as invasiveness, sampling variability and interobservers/intraobservers variability. With the increasing number of NASH patients, there is an urgent need for effective therapeutic agents, and a more urgent need to develop non-invasive markers to screen, diagnose and monitor patients, and evaluate the efficacy. This article reviews the research progress in non-invasive diagnosis of non-alcoholic fatty liver disease, including assessment of steatosis, diagnosis of NASH, and assessment of liver fibrosis.

     

/

返回文章
返回